(Bloomberg) -- JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs. Most Read from BloombergApple to ‘Pay’ OpenAI for ChatGPT Through Distribution, Not CashHunter Biden Was Convicted. His Dad’s Reaction Was Remarkable.US Inflation Broadly Cools in Encouraging Sign for Fed OfficialsFed Officials Dial Back Rate Forecasts, Signal Just One ‘24 CutChinese Trader’s $20 Million
(Bloomberg) -- Argentina’s President Javier Milei scored a partial victory in congress as senators approved his omnibus bill but rejected additional income tax legislation in an overnight debate marred by violent protests on the streets of Buenos Aires. Most Read from BloombergApple to ‘Pay’ OpenAI for ChatGPT Through Distribution, Not CashHunter Biden Was Convicted. His Dad’s Reaction Was Remarkable.US Inflation Broadly Cools in Encouraging Sign for Fed OfficialsFed Officials Dial Back Rate For
In the last year, many JPMorgan Chase & Co. ( NYSE:JPM ) insiders sold a substantial stake in the company which may...